Detalhe da pesquisa
1.
Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection.
Antimicrob Agents Chemother
; 62(9)2018 09.
Artigo
Inglês
| MEDLINE | ID: mdl-29987139
2.
Long-term safety study of fosamprenavir-containing regimens in HIV-1-infected patients.
HIV Clin Trials
; 14(5): 183-91, 2013.
Artigo
Inglês
| MEDLINE | ID: mdl-24144895
3.
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
J Antimicrob Chemother
; 64(2): 398-410, 2009 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-19515730
4.
Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women.
HIV Clin Trials
; 8(6): 371-80, 2007.
Artigo
Inglês
| MEDLINE | ID: mdl-18042502
5.
Psychiatric Symptoms in Patients Receiving Dolutegravir.
J Acquir Immune Defic Syndr
; 74(4): 423-431, 2017 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27984559
6.
Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Clin Ther
; 28(5): 745-54, 2006 May.
Artigo
Inglês
| MEDLINE | ID: mdl-16861096
7.
Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens.
Open AIDS J
; 9: 38-44, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-26157536
8.
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.
Lancet HIV
; 2(4): e127-36, 2015 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-26424673
9.
Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.
Antivir Ther
; 20(3): 343-8, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-25321146
10.
Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO.
J Int AIDS Soc
; 17(4 Suppl 3): 19490, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-25393999
11.
Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data.
Pediatr Infect Dis J
; 33(1): 57-62, 2014 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-23811743
12.
Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.
Pediatr Infect Dis J
; 33(1): 50-6, 2014 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-23811744
13.
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
J Acquir Immune Defic Syndr
; 55(1): 49-57, 2010 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-20431394